RecruitingNCT01884051
Hormonal, Metabolic, and Signaling Interactions in PAH
Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension
Sponsor
Vanderbilt University Medical Center
Enrollment
1,899 participants
Start Date
Sep 1, 2012
Study Type
OBSERVATIONAL
Conditions
Summary
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
Eligibility
Max Age: 90 Years
Inclusion Criteria7
- Project 1
- Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons
- Age 0-90, age 12-90 for skin biopsy
- Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
- Subjects with reasonably easy access to clinic for blood collection and other testing
- Subject able to tolerate fasting state prior to sample collection and EndoPAT (endothelial function assessment) testing
- Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
Exclusion Criteria11
- Other diagnosis
- Age greater than 90, age less than 12 or greater than 90 for skin biopsy
- Project 2
- Other diagnosis
- Subjects with difficulty reaching clinic for blood collection and other testing
- Subjects unable to tolerate fasting state
- Project 3
- Other diagnosis
- Age less than 7 or greater than 90
- \-
- \-
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01884051
Related Trials
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
NCT055847221 location
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
NCT061042281 location
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
NCT054625741 location